{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:51:04Z","timestamp":1790812264858,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.beem.2022.101667","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:42:48Z","timestamp":1652143368000},"page":"101667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effects of endocrine disorders on lipids and lipoproteins"],"prefix":"10.1016","volume":"37","author":[{"given":"Connie B.","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.beem.2022.101667_bib1","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9254","key":"10.1016\/j.beem.2022.101667_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism. West midlands prospective hypopituitary study group","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.beem.2022.101667_bib4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1507\/endocrj.EJ15-0337","article-title":"Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]","volume":"62","author":"Giovannini","year":"2015","journal-title":"Endocr J"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2022.101667_bib5","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1530\/EJE-09-0258","article-title":"Adult GH deficiency throughout lifetime","volume":"161","author":"Thomas","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib6","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1210\/jc.2005-2566","article-title":"The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis","volume":"91","author":"Colao","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/EJE-06-0652","article-title":"Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy","volume":"156","author":"Rizzo","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2022.101667_bib8","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1210\/endo.136.9.7649083","article-title":"Growth hormone specifically stimulates the expression of low density lipoprotein receptors in human hepatoma cells","volume":"136","author":"Parini","year":"1995","journal-title":"Endocrinology"},{"issue":"15","key":"10.1016\/j.beem.2022.101667_bib9","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1073\/pnas.89.15.6983","article-title":"Importance of growth hormone for the induction of hepatic low density lipoprotein receptors","volume":"89","author":"Rudling","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib10","first-page":"2010","article-title":"Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency","volume":"82","author":"Cummings","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/EJE-12-1083","article-title":"Fifteen years of GH replacement improves body composition and cardiovascular risk factors","volume":"168","author":"Elbornsson","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib12","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2003-030840","article-title":"Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials","volume":"89","author":"Maison","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-014-0571-z","article-title":"Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials","volume":"18","author":"Newman","year":"2015","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.beem.2022.101667_bib14","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1210\/jcem.86.10.7887","article-title":"A\u00a0prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices","volume":"86","author":"Gotherstrom","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib15","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1210\/jcem.87.5.8482","article-title":"Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults","volume":"87","author":"Svensson","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/01.ATV.13.2.296","article-title":"Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations","volume":"13","author":"Eden","year":"1993","journal-title":"Arterioscler Thromb"},{"issue":"Pt 4","key":"10.1016\/j.beem.2022.101667_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/000456329603300408","article-title":"Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency","volume":"33","author":"O'Halloran","year":"1996","journal-title":"Ann Clin Biochem"},{"issue":"9","key":"10.1016\/j.beem.2022.101667_bib18","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1210\/jc.2007-0458","article-title":"Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone","volume":"92","author":"Holmer","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2265.2011.04137.x","article-title":"Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency","volume":"75","author":"Schneider","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib20","first-page":"307","article-title":"Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study","volume":"84","author":"Christ","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.clnu.2009.08.015","article-title":"Growth hormone and protein metabolism","volume":"28","author":"Moller","year":"2009","journal-title":"Clin Nutr"},{"issue":"7","key":"10.1016\/j.beem.2022.101667_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/0026-0495(80)90112-2","article-title":"Decline of postheparin plasma lipoprotein lipase in acromegalic patients","volume":"29","author":"Murase","year":"1980","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2265.2001.01326.x","article-title":"The atherogenic plasma remnant-like particle cholesterol concentration is increased in the fasting and postprandial state in active acromegalic patients","volume":"55","author":"Twickler","year":"2001","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib24","first-page":"358","article-title":"The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients","volume":"100","author":"Takeda","year":"1982","journal-title":"Acta Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2265.2012.04414.x","article-title":"GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly","volume":"77","author":"Boero","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0021-9150(00)00433-0","article-title":"Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins","volume":"153","author":"Beentjes","year":"2000","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0021-9150(99)00426-8","article-title":"LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group","volume":"151","author":"Arosio","year":"2000","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2265.1994.tb01825.x","article-title":"Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy","volume":"41","author":"Oscarsson","year":"1994","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2022.101667_bib29","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1210\/jc.2014-2259","article-title":"Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk","volume":"99","author":"Reyes-Vidal","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12020-018-1797-8","article-title":"Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicetre cohort, and review of the literature","volume":"63","author":"Briet","year":"2019","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.beem.2022.101667_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2007-1003343","article-title":"Effects of octreotide on lipid metabolism in acromegaly","volume":"24","author":"Cohen","year":"1992","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2265.2008.03181.x","article-title":"Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly","volume":"69","author":"Delaroudis","year":"2008","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2265.2002.01460.x","article-title":"Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly","volume":"56","author":"Parkinson","year":"2002","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib34","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","article-title":"Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant","volume":"87","author":"Sesmilo","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-130-6-199903160-00021","article-title":"Lipoprotein(a) in acromegaly","volume":"130","author":"Maffei","year":"1999","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.0954-6820.1988.tb15881.x","article-title":"Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984","volume":"223","author":"Bengtsson","year":"1988","journal-title":"Acta Med Scand"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2022.101667_bib38","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib39","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1210\/jcem-48-5-887","article-title":"Regulatory role of triiodothyronine in the degradation of low density lipoprotein by cultured human skin fibroblasts","volume":"48","author":"Chait","year":"1979","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101667_bib40","series-title":"Endotext. South Dartmouth (MA)","article-title":"The effect of endocrine disorders on lipids and lipoproteins","author":"Feingold","year":"2020"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib41","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1210\/jcem.83.5.4759","article-title":"Increased oxidizability of low-density lipoproteins in hypothyroidism","volume":"83","author":"Diekman","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1081\/ERC-200036185","article-title":"Effect of thyroid function on LDL oxidation in hypothyroidism and hyperthyroidism","volume":"30","author":"Oge","year":"2004","journal-title":"Endocr Res"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archinte.160.4.526","article-title":"The Colorado thyroid disease prevalence study","volume":"160","author":"Canaris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1507\/endocrj.K11E-012","article-title":"Multi-center study on the prevalence of hypothyroidism in patients with hypercholesterolemia","volume":"58","author":"Tagami","year":"2011","journal-title":"Endocr J"},{"issue":"9","key":"10.1016\/j.beem.2022.101667_bib45","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbalip.2007.05.001","article-title":"Activation of the hepatic LDL receptor promoter by thyroid hormone","volume":"1771","author":"Lopez","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0006-2952(98)00119-1","article-title":"Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression","volume":"56","author":"Ness","year":"1998","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07435800009040142","article-title":"The regulatory effects of thyroid hormone on the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase","volume":"26","author":"Choi","year":"2000","journal-title":"Endocr Res"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/thy.2018.0416","article-title":"Thyroid and cardiovascular disease: research agenda for enhancing knowledge, prevention, and treatment","volume":"29","author":"Cappola","year":"2019","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00000441-200603000-00008","article-title":"Severe primary hypothyroidism manifesting with torsades de pointes","volume":"331","author":"Schenck","year":"2006","journal-title":"Am J Med Sci"},{"issue":"16","key":"10.1016\/j.beem.2022.101667_bib50","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jacc.2018.02.045","article-title":"Thyroid hormones and cardiovascular function and diseases","volume":"71","author":"Razvi","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.beem.2022.101667_bib51","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.295.9.1033","article-title":"Thyroid status, cardiovascular risk, and mortality in older adults","volume":"295","author":"Cappola","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.beem.2022.101667_bib52","doi-asserted-by":"crossref","first-page":"832","DOI":"10.7326\/0003-4819-148-11-200806030-00225","article-title":"Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality","volume":"148","author":"Ochs","year":"2008","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.beem.2022.101667_bib53","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/jama.2010.1361","article-title":"Subclinical hypothyroidism and the risk of coronary heart disease and mortality","volume":"304","author":"Rodondi","year":"2010","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib54","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1210\/jc.2015-1438","article-title":"Subclinical hypothyroidism and the risk of stroke events and fatal stroke: an individual participant data analysis","volume":"100","author":"Chaker","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2022.101667_bib55","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib56","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11102-015-0645-6","article-title":"Comorbidities in Cushing's disease","volume":"18","author":"Sharma","year":"2015","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2022.101667_bib57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000314213","article-title":"Pathophysiology of dyslipidemia in Cushing's syndrome","volume":"92","author":"Arnaldi","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2022.101667_bib58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4939-2895-8_6","article-title":"How do glucocorticoids regulate lipid metabolism?","volume":"872","author":"de Guia","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib59","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1432-1033.1996.0451u.x","article-title":"Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein","volume":"239","author":"Saladin","year":"1996","journal-title":"Eur J Biochem"},{"issue":"10","key":"10.1016\/j.beem.2022.101667_bib60","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-2275(20)37304-1","article-title":"Glucocorticoid increases rat apolipoprotein A-I promoter activity","volume":"37","author":"Taylor","year":"1996","journal-title":"J\u00a0Lipid Res"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib61","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing's syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib62","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","article-title":"Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2022.101667_bib63","first-page":"2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib64","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2002-021558","article-title":"Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission","volume":"88","author":"Faggiano","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101667_bib65","first-page":"e38","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"38","author":"Newman","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.beem.2022.101667_bib66","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1210\/JC.2015-2080","article-title":"Lipoprotein-free mitotane exerts high cytotoxic activity in adrenocortical carcinoma","volume":"100","author":"Hescot","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2022.101667_bib67","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000314294","article-title":"Management of dyslipidemia in Cushing's syndrome","volume":"92","author":"Greenman","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib68","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.2011-2813","article-title":"Impact of mifepristone, a glucocorticoid\/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function","volume":"97","author":"Page","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2022.101667_bib69","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0026-0495(88)90067-4","article-title":"Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men","volume":"37","author":"Ettinger","year":"1988","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib70","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0026-0495(84)90006-4","article-title":"The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study","volume":"33","author":"Zimmerman","year":"1984","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.beem.2022.101667_bib71","doi-asserted-by":"crossref","first-page":"e0007035","DOI":"10.1371\/journal.pntd.0007035","article-title":"The effects of prednisolone treatment on serological responses and lipid profiles in Ethiopian leprosy patients with Erythema Nodosum Leprosum reactions","volume":"12","author":"Negera","year":"2018","journal-title":"PLoS Neglected Trop Dis"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib72","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1530\/EJE-17-0154","article-title":"Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects","volume":"177","author":"Mazziotti","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib73","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2006.05.019","article-title":"Use of oral corticosteroids and the risk of acute myocardial infarction","volume":"192","author":"Varas-Lorenzo","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2022.101667_bib74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molmet.2018.05.008","article-title":"Sex differences in lipid and lipoprotein metabolism","volume":"15","author":"Palmisano","year":"2018","journal-title":"Mol Metabol"},{"key":"10.1016\/j.beem.2022.101667_bib75","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-319-70178-3_12","article-title":"Role of estrogens in the regulation of liver lipid metabolism","volume":"1043","author":"Palmisano","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib76","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/me.2004-0486","article-title":"Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes","volume":"19","author":"Bjornstrom","year":"2005","journal-title":"Mol Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2022.101667_bib77","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/138920206779315737","article-title":"Estrogen signaling multiple pathways to impact gene transcription","volume":"7","author":"Marino","year":"2006","journal-title":"Curr Genom"},{"key":"10.1016\/j.beem.2022.101667_bib78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-3-319-70178-3_20","article-title":"G-Protein-Coupled estrogen receptor (GPER) and sex-specific metabolic homeostasis","volume":"1043","author":"Sharma","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2010.226","article-title":"Estrogen receptors: therapies targeted to receptor subtypes","volume":"89","author":"Nilsson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib80","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1186\/s12889-019-7901-z","article-title":"Age, maturation and serum lipid parameters: findings from the German Health Survey for Children and Adolescents","volume":"19","author":"Schienkiewitz","year":"2019","journal-title":"BMC Publ Health"},{"issue":"8A","key":"10.1016\/j.beem.2022.101667_bib81","doi-asserted-by":"crossref","first-page":"77i","DOI":"10.1016\/S0002-9149(02)02637-1","article-title":"Lipoprotein abnormalities related to women's health","volume":"90","author":"Bittner","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beem.2022.101667_bib82","first-page":"185","article-title":"Dyslipidemia in women: etiology and management","volume":"6","author":"Phan","year":"2014","journal-title":"Int J Womens Health"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib83","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1210\/jc.2010-2061","article-title":"Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones","volume":"96","author":"Wang","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2022.101667_bib84","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11886-015-0609-5","article-title":"Dyslipidemia and cardiovascular disease in women","volume":"17","author":"Cifkova","year":"2015","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0021-9150(00)00609-2","article-title":"Effects of age at menopause on serum cholesterol, body mass index, and blood pressure","volume":"156","author":"Akahoshi","year":"2001","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.beem.2022.101667_bib86","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.beem.2022.101667_bib87","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"Zhu","year":"2019","journal-title":"Lancet Public Health"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib88","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.beem.2022.101667_bib89","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib90","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.amjmed.2010.09.021","article-title":"Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes","volume":"124","author":"Harman","year":"2011","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib91","first-page":"CD002229","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.beem.2022.101667_bib92","doi-asserted-by":"crossref","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.beem.2022.101667_bib93","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1161\/STROKEAHA.116.013052","article-title":"Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen","volume":"47","author":"Canonico","year":"2016","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.beem.2022.101667_bib94","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/GME.0000000000001868","article-title":"Menopausal hormone therapy and hypertension: minimizing risk","volume":"28","author":"Mehta","year":"2021","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib95","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacl.2016.12.006","article-title":"Estrogen-associated severe hypertriglyceridemia with pancreatitis","volume":"11","author":"Aljenedil","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"issue":"1\u20132","key":"10.1016\/j.beem.2022.101667_bib96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0009-8981(03)00129-3","article-title":"An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia","volume":"332","author":"Goldenberg","year":"2003","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1572-0241.2006.00924.x","article-title":"Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a population-based case-control study","volume":"102","author":"Tetsche","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib98","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMcp1514916","article-title":"CLINICAL PRACTICE. Polycystic ovary syndrome","volume":"375","author":"McCartney","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.beem.2022.101667_bib99","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9343(01)00948-2","article-title":"Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome","volume":"111","author":"Legro","year":"2001","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib100","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1210\/jc.2006-1705","article-title":"Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome","volume":"92","author":"Berneis","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2022.101667_bib101","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1210\/jc.2007-1756","article-title":"A\u00a0more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study","volume":"93","author":"Valkenburg","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib102","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2265.2001.01245.x","article-title":"Smaller LDL particle size in women with polycystic ovary syndrome compared to controls","volume":"54","author":"Dejager","year":"2001","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib103","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2265.2001.01228.x","article-title":"Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters","volume":"54","author":"Pirwany","year":"2001","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib104","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.fertnstert.2010.12.027","article-title":"Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis","volume":"95","author":"Wild","year":"2011","journal-title":"Fertil Steril"},{"issue":"9","key":"10.1016\/j.beem.2022.101667_bib105","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/humrep\/dep121","article-title":"Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype","volume":"24","author":"Rizzo","year":"2009","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib106","doi-asserted-by":"crossref","first-page":"E841","DOI":"10.1210\/jc.2013-3918","article-title":"Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS","volume":"99","author":"Roe","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib107","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7861\/clinmedicine.16-3-262","article-title":"Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance","volume":"16","author":"Barber","year":"2016","journal-title":"Clin Med"},{"issue":"12","key":"10.1016\/j.beem.2022.101667_bib108","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1210\/jc.2011-1677","article-title":"Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study","volume":"96","author":"Schmidt","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.beem.2022.101667_bib110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/jc.2008-1750","article-title":"The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study","volume":"94","author":"Sathyapalan","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2022.101667_bib111","first-page":"CD008565","article-title":"Statins for women with polycystic ovary syndrome not actively trying to conceive","author":"Raval","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.beem.2022.101667_bib112","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1210\/jc.2013-2674","article-title":"Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study","volume":"98","author":"Puurunen","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib113","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.fertnstert.2010.11.040","article-title":"Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial","volume":"95","author":"Raja-Khan","year":"2011","journal-title":"Fertil Steril"},{"issue":"Pt 1","key":"10.1016\/j.beem.2022.101667_bib114","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1258\/acb.2011.011071","article-title":"Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study","volume":"49","author":"Sathyapalan","year":"2012","journal-title":"Ann Clin Biochem"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib115","first-page":"912","article-title":"Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial","volume":"59","author":"Rashidi","year":"2011","journal-title":"J\u00a0Invest Med"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib116","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-111-4-288","article-title":"Elevated serum lipids in hypogonadal men with and without hyperprolactinemia","volume":"111","author":"Oppenheim","year":"1989","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib117","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.numecd.2007.01.014","article-title":"Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Tromso study","volume":"18","author":"Agledahl","year":"2008","journal-title":"Nutr Metabol Cardiovasc Dis : Nutr Metabol Cardiovasc Dis"},{"issue":"9","key":"10.1016\/j.beem.2022.101667_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162480","article-title":"Treatment of men for \"low testosterone\": a systematic review","volume":"11","author":"Huo","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib119","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/eje.1.02166","article-title":"Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes","volume":"154","author":"Kapoor","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib120","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2337\/dc06-1426","article-title":"Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity","volume":"30","author":"Kapoor","year":"2007","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib121","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/dc10-1233","article-title":"Testosterone replacement in hypogonadal men with type 2 diabetes and\/or metabolic syndrome (the TIMES2 study)","volume":"34","author":"Jones","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib122","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1365-2265.1999.00882.x","article-title":"Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy","volume":"51","author":"Tan","year":"1999","journal-title":"Clin Endocrinol"},{"issue":"2\u20133","key":"10.1016\/j.beem.2022.101667_bib123","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0021-9150(88)90014-7","article-title":"Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males","volume":"69","author":"Sorva","year":"1988","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.beem.2022.101667_bib124","doi-asserted-by":"crossref","first-page":"E1112","DOI":"10.1152\/ajpendo.00524.2002","article-title":"Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk","volume":"284","author":"Herbst","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0006-291X(02)02038-7","article-title":"Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages","volume":"296","author":"Langer","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.beem.2022.101667_bib126","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society clinical Practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2022.101667_bib127","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0026-0495(84)90222-1","article-title":"Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids","volume":"33","author":"Webb","year":"1984","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib128","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-2007-1024704","article-title":"Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders","volume":"12","author":"Kuipers","year":"1991","journal-title":"Int J Sports Med"},{"issue":"4","key":"10.1016\/j.beem.2022.101667_bib129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.1984.03350040037019","article-title":"High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use","volume":"252","author":"Hurley","year":"1984","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.beem.2022.101667_bib130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1210\/er.2013-1058","article-title":"Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement","volume":"35","author":"Pope","year":"2014","journal-title":"Endocr Rev"},{"issue":"Pt 1","key":"10.1016\/j.beem.2022.101667_bib131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainresbull.2016.05.003","article-title":"The neurobiology and addiction potential of anabolic androgenic steroids and the effects of growth hormone","volume":"126","author":"Gronbladh","year":"2016","journal-title":"Brain Res Bull"},{"issue":"7","key":"10.1016\/j.beem.2022.101667_bib132","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1210\/jc.2018-01882","article-title":"Diagnosis and management of anabolic androgenic steroid use","volume":"104","author":"Anawalt","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2022.101667_bib133","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2017-01643","article-title":"Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Maraka","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:59:05Z","timestamp":1761497945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1521690X22000549"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101667","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of endocrine disorders on lipids and lipoproteins","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101667"}}